Weekly Trademark Review – Issued July 19, 2011
This article was originally published in The Rose Sheet
You may also be interested in...
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.